☆ 4.6 Letter

The potential impact of azithromycin in idiopathic pulmonary fibrosis

EUROPEAN RESPIRATORY JOURNAL (2019)

期刊

EUROPEAN RESPIRATORY JOURNAL

卷 53, 期 2, 页码 -

出版社

EUROPEAN RESPIRATORY SOC JOURNALS LTD

DOI: 10.1183/13993003.00628-2018

关键词

-

类别

Respiratory System

资金

National Institute for Health Research (NIHR) [CS-2013-13-017]
British Lung Foundation Chair in Respiratory Research [C17-3]
NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Respiratory System

Azithromycin for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis A Randomized Controlled Crossover Trial

Sabina A. Guler, Christian Clarenbach, Martin Brutsche, Katrin Hostettler, Anne-Kathrin Brill, Anke Schertel, Thomas K. Geiser, Manuela Funke-Chambour

Summary: This study did not support the use of low-dose azithromycin for chronic cough in patients with IPF. Gastrointestinal adverse effects were more frequent with azithromycin than with placebo.

ANNALS OF THE AMERICAN THORACIC SOCIETY (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

CC Chemokines in Idiopathic Pulmonary Fibrosis: Pathogenic Role and Therapeutic Potential

Shanshan Liu, Chang Liu, Qianrong Wang, Suosi Liu, Jiali Min

Summary: Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive respiratory disease characterized by irreversible decline in lung function. The dysregulated expression of chemokines and chemokine receptors has been associated with the development and progression of IPF. Chemokines of the CC family play significant roles in exacerbating IPF progression. Modulating levels of detrimental CC chemokines and interrupting the corresponding transduction axis by neutralizing antibodies or antagonists are potential treatment options for IPF. This review focuses on the roles of different CC chemokines in IPF pathogenesis and their potential use as biomarkers or therapeutic targets.

BIOMOLECULES (2023)

添加到收藏夹

Article Critical Care Medicine

Managing Cough in Idiopathic Pulmonary Fibrosis

Yosafe Wakwaya, Deepa Ramdurai, Jeffrey J. Swigris

Summary: Chronic cough in patients with IPF may involve multiple mechanisms, including comorbid conditions and IPF itself. Diagnostic and management approaches need to be multi-faceted, but may lack robust data support.

CHEST (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

The identification of metabolism-related subtypes and potential treatments for idiopathic pulmonary fibrosis

Changqing Yang, Guixin Wang, Wenyu Zhan, Yubao Wang, Jing Feng

Summary: This study identified IPF subtypes based on metabolism-related pathways and explored potential drugs for each subtype. Two subtypes with significant prognosis differences were discovered, with subtype C1 having a poor prognosis, low metabolic levels, and a unique immune signature. Finally, subtype-specific drugs for potential IPF treatment were identified.

FRONTIERS IN PHARMACOLOGY (2023)

添加到收藏夹

Article Respiratory System

Impact of antifibrotic therapy on lung cancer development in idiopathic pulmonary fibrosis

Hyogo Naoi, Yuzo Suzuki, Kazutaka Mori, Yuya Aono, Masato Kono, Hirotsugu Hasegawa, Koshi Yokomura, Yusuke Inoue, Hironao Hozumi, Masato Karayama, Kazuki Furuhashi, Noriyuki Enomoto, Tomoyuki Fujisawa, Yutaro Nakamura, Naoki Inui, Hidenori Nakamura, Takafumi Suda

Summary: Antifibrotic therapy may reduce the risk of lung cancer development in patients with idiopathic pulmonary fibrosis (IPF) and potentially prolong their survival.

THORAX (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Discovery of indoline-based derivatives as effective ROCK2 inhibitors for the potential new treatment of idiopathic pulmonary fibrosis

Suhong Fu, Yi Wen, Bin Peng, Minghai Tang, Mingsong Shi, Jiang Liu, Yingxue Yang, Wenting Si, Yong Guo, Xiandeng Li, Tingting Yan, Jie Kang, Heying Pei, Lijuan Chen

Summary: Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease with a short median survival. Rho-associated coiled-coil protein kinases (ROCKs) have been identified as potential targets for IPF treatment. A new series of selective ROCK2 inhibitors based on indoline were designed and synthesized. Compound 9b showed promising activity against ROCK2 and collagen gel contraction. In animal models, oral administration of 9b demonstrated significant antipulmonary fibrosis effects compared to currently used drugs.

BIOORGANIC CHEMISTRY (2023)

添加到收藏夹

Review Biochemistry & Molecular Biology

The Role of Microbiome and Virome in Idiopathic Pulmonary Fibrosis

Paschalis Ntolios, Vassilios Tzilas, Evangelos Bouros, Eleni Avdoula, Ioannis Karakasiliotis, Demosthenes Bouros, Paschalis Steiropoulos

Summary: The interest in the lung microbiome and virome and their contribution to the pathogenesis of idiopathic pulmonary fibrosis (IPF) has been increasing. Higher microbial burden is associated with worse prognosis but no specific microbe has been identified to contribute to this. Infection is considered a cause of acute exacerbation of IPF, but the association of viral infection with AE-IPF has not been established.

BIOMEDICINES (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Azithromycin Attenuates Bleomycin-Induced Pulmonary Fibrosis Partly by Inhibiting the Expression of LOX and LOXL-2

Xiang Tong, Shijie Zhang, Dongguang Wang, Li Zhang, Jizheng Huang, Tianli Zhang, Hong Fan

Summary: Azithromycin (AZM) effectively attenuates BLM-induced pulmonary fibrosis in mice by partially inhibiting the JNK/c-Jun and TGF-beta 1/Smad signaling pathways and reducing production of LOX and LOXL2.

FRONTIERS IN PHARMACOLOGY (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Clinicopathological Outlines of Post-COVID-19 Pulmonary Fibrosis Compared with Idiopathic Pulmonary Fibrosis

Roxana-Elena Cirjaliu, Mariana Deacu, Ioana Gherghisan, Angela Stefania Marghescu, Manuela Enciu, Gabriela Izabela Baltatescu, Antonela Anca Nicolau, Doina-Ecaterina Tofolean, Oana Cristina Arghir, Ariadna-Petronela Fildan

Summary: This review provides a comprehensive analysis of the risk factors, clinical, radiologic, and histological features of both post-COVID-19 pulmonary fibrosis (PCPF) and idiopathic pulmonary fibrosis (IPF). It highlights the similarities and differences between these two diseases by gathering relevant articles published in English up until October 2022 using multiple databases. This review aims to assist clinicians, pathologists, and researchers in making accurate diagnoses and selecting patients for anti-fibrotic therapies and future therapeutic perspectives.

BIOMEDICINES (2023)

添加到收藏夹

Review Pharmacology & Pharmacy

New insights into the Hippo/YAP pathway in idiopathic pulmonary fibrosis

Mingyao Sun, Yangyang Sun, Ziru Feng, Xinliang Kang, Weijie Yang, Yongan Wang, Yuan Luo

Summary: IPF is a progressive disease characterized by an inexorable decline in lung function, involving multiple positive feedback loops and the crucial role of the Hippo/YAP signaling pathway. YAP/TAZ plays a key role in pulmonary fibrosis and alveolar regeneration by regulating cell proliferation and extracellular matrix deposition through different signaling pathways.

PHARMACOLOGICAL RESEARCH (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Perspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis

Xudan Yang, Zhihao Xu, Songhua Hu, Juan Shen

Summary: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease without a known cause. Current approved drugs for IPF, such as Pirfenidone and Nintedanib, can slow down the decline in lung function and reduce the risk of acute worsening. However, they cannot alleviate symptoms or improve overall survival. The development of new, safe, and effective drugs is necessary. Previous studies have shown that cyclic nucleotides and phosphodiesterase inhibitors may be potential targets for treating pulmonary fibrosis. This paper reviews the progress in research on PDE inhibitors and provides insights for the development of anti-pulmonary fibrosis drugs.

FRONTIERS IN PHARMACOLOGY (2023)

添加到收藏夹

Review Medicine, General & Internal

Idiopathic Pulmonary Fibrosis and Telomeres

Alba Mulet, Jaime Signes-Costa

Summary: Idiopathic pulmonary fibrosis is a lung disease with unknown causes, which has a poor prognosis. Telomeric shortening may play an important role in its pathogenesis, but mutations in telomere-related genes are not always present. Telomere shortening can serve as a biomarker for disease prognosis independently of other clinical factors.

JOURNAL OF CLINICAL MEDICINE (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Small airway dysfunction in idiopathic pulmonary fibrosis

Chengsheng Yin, Huikang Xie, Xian He, Yuan Zhang, Aihong Zhang, Huiping Li

Summary: This study aimed to investigate the occurrence of small airway dysfunction (SAD) comorbidity in idiopathic pulmonary fibrosis (IPF) and its impact on survival. The study found that 34.57% of IPF patients were diagnosed with SAD, and comorbid SAD was an independent risk factor for mortality in IPF patients.

FRONTIERS IN PHARMACOLOGY (2022)

添加到收藏夹

Review Medicine, General & Internal

Potential biomarkers for diagnosis and disease evaluation of idiopathic pulmonary fibrosis

Qing Wang, Zhaoliang Xie, Nansheng Wan, Lei Yang, Zhixian Jin, Fang Jin, Zhaoming Huang, Min Chen, Huiming Wang, Jing Feng

Summary: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with poor prognosis and variable disease courses. Biomarkers have been identified in different categories to aid in the differential diagnosis, disease progression prediction, and treatment evaluation of IPF. However, most biomarkers are not commonly used in clinical practice and further studies are needed to validate their diagnostic utility.

CHINESE MEDICAL JOURNAL (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

Distal Lung Microenvironment Triggers Release of Mediators Recognized as Potential Systemic Biomarkers for Idiopathic Pulmonary Fibrosis

Dimitrios Kalafatis, Anna Loefdahl, Per Naesman, Goeran Dellgren, Asa M. Wheelock, Linda Elowsson Rendin, Magnus Skoeld, Gunilla Westergren-Thorsson

Summary: This study utilized a novel ex vivo model to investigate the association between protein changes in serum of patients with idiopathic pulmonary fibrosis (IPF) and disease severity and treatment response. The findings support the applicability of the model in studying IPF mechanisms and provide additional evidence for established and potentially new biomarkers in IPF.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Article Rheumatology

Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease

Michael Kreuter, Anna-Maria Hoffmann-Vold, Marco Matucci-Cerinic, Lesley Ann Saketkoo, Kristin B. Highland, Hilary Wilson, Margarida Alves, Elvira Erhardt, Nils Schoof, Toby M. Maher

Summary: This study found that the severity of SSc-ILD and significant deteriorations in lung function are associated with a major impact on health-related quality of life (HRQoL). Treatments that slow lung function decline and prevent severe SSc-ILD are important for preserving HRQoL.

RHEUMATOLOGY (2023)

添加到收藏夹

Article Critical Care Medicine

Longitudinal lung function and gas transfer in individuals with idiopathic pulmonary fibrosis: a genome-wide association study

Richard J. Allen, Justin M. Oldham, David A. Jenkins, Olivia C. Leavy, Beatriz Guillen-Guio, Carl A. Melbourne, Shwu-Fan Ma, Jonathan Jou, John S. Kim, William A. Fahy, Eunice Oballa, Richard B. Hubbard, Vidya Navaratnam, Rebecca Braybrooke, Gauri Saini, Katy M. Roach, Martin D. Tobin, Nik Hirani, Moira K. B. Whyte, Naftali Kaminski, Yingze Zhang, Fernando J. Martinez, Angela L. Linderholm, Ayodeji Adegunsoye, Mary E. Strek, Toby M. Maher, Philip L. Molyneaux, Carlos Flores, Imre Noth, R. Gisli Jenkins, Louise Wain

Summary: In this study, a genetic variant associated with disease progression in idiopathic pulmonary fibrosis (IPF) was identified, and the PKN2 gene was proposed as a potential target for novel therapeutic approaches. This finding provides insights into the biological mechanisms underlying IPF and offers potential implications for its treatment.

LANCET RESPIRATORY MEDICINE (2023)

添加到收藏夹

Article Critical Care Medicine

Idiopathic Pulmonary Fibrosis Is Associated with Common Genetic Variants and Limited Rare Variants

Anna L. Peljto, Rachel Z. Blumhagen, Avram D. Walts, Jonathan Cardwell, Julia Powers, Tamera J. Corte, Joanne L. Dickinson, Ian Glaspole, Yuben P. Moodley, Martina Koziar Vasakova, Elisabeth Bendstrup, Jesper R. Davidsen, Raphael Borie, Bruno Crestani, Philippe Dieude, Francesco Bonella, Ulrich Costabel, Gunnar Gudmundsson, Seamas C. Donnelly, Jim Egan, Michael T. Henry, Michael P. Keane, Marcus P. Kennedy, Cormac McCarthy, Aoife N. McElroy, Joshua A. Olaniyi, Katherine M. A. O'Reilly, Luca Richeldi, Paolo M. Leone, Venerino Poletti, Francesco Puppo, Sara Tomassetti, Valentina Luzzi, Nurdan Kokturk, Nesrin Mogulkoc, Christine A. Fiddler, Nikhil Hirani, R. Gisli Jenkins, Toby M. Maher, Philip L. Molyneaux, Helen Parfrey, Rebecca Braybrooke, Timothy S. Blackwell, Peter D. Jackson, Steven D. Nathan, Mary K. Porteous, Kevin K. Brown, Jason D. Christie, Harold R. Collard, Oliver Eickelberg, Elena E. Foster, Kevin F. Gibson, Marilyn Glassberg, Daniel J. Kass, Jonathan A. Kropski, David Lederer, Angela L. Linderholm, Jim Loyd, Susan K. Mathai, Sydney B. Montesi, Imre Noth, Justin M. Oldham, Amy J. Palmisciano, Cristina A. Reichner, Mauricio Rojas, Jesse Roman, Neil Schluger, Barry S. Shea, Jeffrey J. Swigris, Paul J. Wolters, Yingze Zhang, Cecilia M. A. Prele, Juan I. Enghelmayer, Maria Otaola, Christopher J. Ryerson, Mauricio Salinas, Martina Sterclova, Tewodros H. Gebremariam, Marjukka Myllarniemi, Roberto G. Carbone, Haruhiko Furusawa, Masaki Hirose, Yoshikazu Inoue, Yasunari Miyazaki, Ken Ohta, Shin Ohta, Tsukasa Okamoto, Dong Soon Kim, Annie Pardo, Moises Selman, Alvaro U. Aranda, Moo Suk Park, Jong Sun Park, Jin Woo Song, Maria Molina-Molina, Lurdes Planas-Cerezales, Gunilla Westergren-Thorsson, Albert V. Smith, Ani W. Manichaikul, John S. Kim, Stephen S. Rich, Elizabeth C. Oelsner, R. Graham Barr, Jerome I. Rotter, Josee Dupuis, George O'Connor, Ramachandran S. Vasan, Michael H. Cho, Edwin K. Silverman, Marvin I. Schwarz, Mark P. Steele, Joyce S. Lee, Ivana V. Yang, Tasha E. Fingerlin, David A. Schwartz

Summary: This study investigated the role of rare variants, genome-wide, on the risk of idiopathic pulmonary fibrosis (IPF) using whole-genome sequencing. The results showed that rare variants within the TERT and RTEL1 genes were significantly associated with IPF, along with well-established common variants. Therefore, including TERT, RTEL1, common variants, and environmental risk factors in risk profiling and IPF therapy development is likely to have the largest impact on this complex disease.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2023)

添加到收藏夹

Article Respiratory System

Study protocol of an international patient-led registry in patients with pulmonary fibrosis using online home monitoring: I-FILE

Gizal Nakshbandi, Catharina C. Moor, Katerina Antoniou, Vincent Cottin, Anna-Maria Hoffmann-Vold, Edwin A. Koemans, Michael Kreuter, Philip L. Molyneaux, Wim A. Wuyts, Marlies S. Wijsenbeek

Summary: This study aims to assess long-term FVC change in patients with PF measured with home spirometry and evaluate the feasibility of a multinational patient-led registry in PF. In addition, the validity of patient-reported outcomes will be assessed for different subgroups of patients with PF.

BMC PULMONARY MEDICINE (2023)

添加到收藏夹

Article Critical Care Medicine

PCSK6 and Survival in Idiopathic Pulmonary Fibrosis

Justin M. Oldham, Richard J. Allen, Jose M. Lorenzo-Salazar, Philip L. Molyneaux, Shwu-Fan Ma, Chitra Joseph, John S. Kim, Beatriz Guillen-Guio, Tamara Hernandez-Beeftink, Jonathan A. Kropski, Yong Huang, Cathryn T. Lee, Ayodeji Adegunsoye, Janelle Vu Pugashetti, Angela L. Linderholm, Vivian Vo, Mary E. Strek, Jonathan Jou, Adrian Munoz-Barrera, Luis A. Rubio-Rodriguez, Richard Hubbard, Nik Hirani, Moira K. B. Whyte, Simon Hart, Andrew G. Nicholson, Lisa Lancaster, Helen Parfrey, Doris Rassl, William Wallace, Eleanor Valenzi, Yingze Zhang, Josyf Mychaleckyj, Amy Stockwell, Naftali Kaminski, Paul J. Wolters, Maria Molina-Molina, Nicholas E. Banovich, William A. Fahy, Fernando J. Martinez, Ian P. Hall, Martin D. Tobin, Toby M. Maher, Timothy S. Blackwell, Brian L. Yaspan, R. Gisli Jenkins, Carlos Flores, Louise V. Wain, Imre Noth

Summary: This study conducted a staged genome-wide association study to identify and validate molecular determinants of survival in idiopathic pulmonary fibrosis (IPF). Four novel variants associated with IPF survival were identified, including one within the PCSK6 gene that reached genome-wide significance. Downstream analyses suggested that PCSK6 protein may play an important role in IPF progression.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2023)

添加到收藏夹

Article Medicine, General & Internal

Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis The ISABELA 1 and 2 Randomized Clinical Trials

Toby M. Maher, Paul Ford, Kevin K. Brown, Ulrich Costabel, Vincent Cottin, Sonye K. Danoff, Irene Groenveld, Eric Helmer, R. Gisli Jenkins, Julie Milner, Geert Molenberghs, Bjorn Penninckx, Matthew J. Randall, Bernt Van den Blink, Ann Fieuw, Charlotte Vandenrijn, Sanda Rocak, Ineke Seghers, Lixin Shao, Amit Taneja, Garrit Jentsch, Timothy R. Watkins, Wim A. Wuyts, Michael Kreuter, Nadia Verbruggen, Niyati Prasad, Marlies S. Wijsenbeek

Summary: This study aimed to assess the efficacy and safety of the autotaxin inhibitor ziritaxestat in patients with idiopathic pulmonary fibrosis (IPF). The study found that ziritaxestat did not improve clinical outcomes compared with placebo in patients with IPF.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)

添加到收藏夹

Article Respiratory System

Change in gait speed and adverse outcomes in patients with idiopathic pulmonary fibrosis: A prospective cohort study

Claire M. Nolan, Susie J. Schofield, Matthew Maddocks, Suhani Patel, Ruth E. Barker, Jessica A. Walsh, Oliver Polgar, Peter M. George, Philip L. Molyneaux, Toby M. Maher, Paul Cullinan, William D. -C. Man

Summary: This study aimed to investigate the longitudinal change of four-metre gait speed (4MGS) in newly diagnosed individuals with idiopathic pulmonary fibrosis (IPF) and its association with adverse outcome. The study found that 4MGS declined over 6 months, and a decline of 0.07 m/s or more was significantly associated with increased risk of hospitalization/death. Therefore, 4MGS change has the potential to serve as a surrogate endpoint for interventions targeting hospitalization/death risk.

RESPIROLOGY (2023)

添加到收藏夹

Article Critical Care Medicine

Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study

Callum Jackson, Iain Stewart, Tatiana Plekhanova, Peter S. Cunningham, Andrew L. Hazel, Bashar Al-Sheklly, Raminder Aul, Charlotte E. Bolton, Trudie Chalder, James D. Chalmers, Nazia Chaudhuri, Annemarie B. Docherty, Gavin Donaldson, Charlotte L. Edwardson, Omer Elneima, Neil J. Greening, Neil A. Hanley, Victoria C. Harris, Ewen M. Harrison, Ling-Pei Ho, Linzy Houchen-Wolloff, Luke S. Howard, Caroline J. Jolley, Mark G. Jones, Olivia C. Leavy, Keir E. Lewis, Nazir Lone, Michael Marks, Hamish J. C. McAuley, Melitta A. McNarry, Brijesh Patel, Karen Piper-Hanley, Krisnah Poinasamy, Betty Raman, Matthew Richardson, Pilar Rivera-Ortega, Sarah L. Rowland-Jones, Alex Rowlands, Ruth M. Saunders, Janet T. Scott, Marco Sereno, Ajay M. Shah, Aarti Shikotra, Amisha Singapuri, Stefan C. Stanel, Mathew Thorpe, Daniel G. Wootton, Thomas Yates, R. Gisli Jenkins, Sally J. Singh, William D-C Man, Christopher E. Brightling, Louise Wain, Joanna C. Porter, A. A. Roger Thompson, Alex Horsley, Philip L. Molyneaux, Rachael A. Evans, Samuel E. Jones, Martin K. Rutter, John F. Blaikley, PHOSP-COVID Study Collaborative Grp

Summary: This study investigated the prevalence and nature of sleep disturbance after discharge following hospital admission for COVID-19 and found that sleep disturbance is associated with dyspnoea, anxiety, and muscle weakness. Targeting sleep disturbance might be beneficial in treating the post-COVID-19 condition.

LANCET RESPIRATORY MEDICINE (2023)

添加到收藏夹

Editorial Material Critical Care Medicine

Knowledge gaps in fibrotic interstitial lung disease in pan-Asian populations: data not missing at random?

Felix Chua, Suying Low, Gin Tsen Chai, Yoshikazu Inoue, Voon Ong, Amornpun Wongkarnjana, Kamon Kawkitinarong, Jin Woo Song, Zuhanis Abdul Hamid, Aida Abdul Aziz, Mae Campomanes, Toby M. Maher, Philip L. Molyneaux, Syazatul Syakirin

LANCET RESPIRATORY MEDICINE (2023)

添加到收藏夹

Article Health Care Sciences & Services

Determinants of recovery from post-COVID-19 dyspnoea: analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls

Bang Zheng, Giulia Vivaldi, Luke Daines, Olivia C. Leavy, Matthew Richardson, Omer Elneima, Hamish J. C. McAuley, Aarti Shikotra, Amisha Singapuri, Marco Sereno, Ruth M. Saunders, Victoria C. Harris, Linzy Houchen-Wolloff, Neil J. Greening, Paul E. Pfeffer, John R. Hurst, Jeremy S. Brown, Manu Shankar-Hari, Carlos Echevarria, Anthony De Soyza, Ewen M. Harrison, Annemarie B. Docherty, Nazir Lone, Jennifer K. Quint, James D. Chalmers, Ling-Pei Ho, Alex Horsley, Michael Marks, Krishna Poinasamy, Betty Raman, Liam G. Heaney, Louise V. Wain, Rachael A. Evans, Christopher E. Brightling, Adrian Martineau, Aziz Sheikh

Summary: This study investigated the determinants of recovery from dyspnoea in adults with COVID-19 and compared them to non-COVID-19 patients. The results showed that the factors associated with dyspnoea recovery in COVID-19 patients were similar to those in non-COVID-19 patients. These factors included age, gender, obesity status, mental health, cardiovascular disease, and length of hospital admission.

LANCET REGIONAL HEALTH-EUROPE (2023)

添加到收藏夹

Article Critical Care Medicine

Combination of BAL and Computed Tomography Differentiates Progressive and Non-progressive Fibrotic Lung Diseases

Joseph L. Barnett, Toby M. Maher, Jennifer K. Quint, Alex Adamson, Zhe Wu, David J. F. Smith, Bhavin Rawal, Arjun Nair, Simon L. F. Walsh, Sujal R. Desai, Peter M. George, Maria Kokosi, Gisli Jenkins, Vasilis Kouranos, Elisabetta A. Renzoni, Alex Rice, Andrew G. Nicholson, Felix Chua, Athol U. Wells, Philip L. Molyneaux, Anand Devaraj

Summary: This study found that increased BAL lymphocyte proportion is rare in patients with extensive fibrosis or a UIP pattern on CT, and in patients without extensive fibrosis or a non-UIP pattern, an increased BAL lymphocyte proportion is associated with a lower likelihood of disease progression.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2023)

添加到收藏夹

Article Oncology

Radiomics-based decision support tool assists radiologists in small lung nodule classification and improves lung cancer early diagnosis

Benjamin Hunter, Christos Argyros, Marianna Inglese, Kristofer Linton-Reid, Ilaria Pulzato, Andrew G. Nicholson, Samuel V. Kemp, Pallav L. Shah, Philip L. Molyneaux, Cillian Mcnamara, Toby Burn, Emily Guilhem, Marcos Mestas Nunez, Julia Hine, Anika Choraria, Prashanthi Ratnakumar, Susannah Bloch, Simon Jordan, Simon Padley, Carole A. Ridge, Graham Robinson, Hasti Robbie, Joseph Barnett, Mario Silva, Sujal Desai, Richard W. Lee, Eric O. Aboagye, Anand Devaraj

Summary: This study developed a radiomics model to assist in the diagnosis of lung cancer. By extracting radiomics features and using clustering methods, patients were stratified into different risk groups. The model showed high accuracy in predicting malignancy and has potential clinical applications.

BRITISH JOURNAL OF CANCER (2023)

添加到收藏夹

Article Respiratory System

Decline in forced vital capacity as a surrogate for mortality in patients with pulmonary fibrosis

Toby M. Maher, Susanne Stowasser, Florian Voss, Elisabeth Bendstrup, Michael Kreuter, Fernando J. Martinez, Patricia J. Sime, Christian Stock

Summary: This study used clinical trial data of nintedanib in patients with pulmonary fibrosis to assess decline in forced vital capacity (FVC) as a surrogate for mortality. The results showed a strong association between the rate of decline in FVC % predicted and the risk of death over 52 weeks, supporting FVC decline as a surrogate for mortality in these patients.

RESPIROLOGY (2023)

添加到收藏夹

Article Respiratory System

The Burden and Impact of Cough in Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the Prospective Observational PROFILE Study

Peter Saunders, Zhe Wu, William A. Fahy, Iain D. Stewart, Gauri Saini, David J. F. Smith, Rebecca Braybrooke, Carmel Stock, Elisabetta A. Renzoni, Simon R. Johnson, R. Gisli Jenkins, Maria G. Belvisi, Jaclyn A. Smith, Toby M. Maher, Philip L. Molyneaux

Summary: This study aims to assess the burden of cough and its impact on quality of life in newly diagnosed IPF patients. The results indicate that cough burden in IPF is high, but cough-specific quality of life does not have prognostic value and is not associated with MUC5B promoter polymorphism.

ANNALS OF THE AMERICAN THORACIC SOCIETY (2023)

添加到收藏夹

Meeting Abstract Respiratory System

Nalbuphine Extended Release Treatment Achieved Rapid and Sustained Reduction in Reported Cough Frequency in Patients with Idiopathic Pulmonary Fibrosis

Toby M. Maher, Thomas Sciascia, Enoch Bortey, Philip L. Molyneaux, Marlies Wijsenbeek, Jaclyn Smith

LUNG (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.